Cambridge Epigenetix
Audrey Vandomme has worked in the scientific field since 2015. Audrey began their career as a postdoctoral fellowship at The Francis Crick Institute, where they worked on a project exploring the role of the pir gene multifamily in Plasmodium chabaudi chabaudi infection. Audrey developed and adapted the CRISPR technology for Plasmodium chabaudi during this time. In 2019, they moved to PredictImmune as a Senior Scientist. Most recently, in 2021, they joined Cambridge Epigenetix as a Senior Scientist.
Audrey Vandomme obtained their Doctor of Philosophy (PhD) in Parasitology from the University of Lille 1 Sciences and Technology in 2014. Prior to that, they completed their Master's degree in Parasitology and Immunology from the same university in 2010.
This person is not in the org chart
This person is not in any offices
Cambridge Epigenetix
Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.